Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC
Lantern Pharma Inc. has secured regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.
Never-smokers | 23/04/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy